TD Private Client Wealth LLC Has $3.24 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

TD Private Client Wealth LLC reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 23.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,218 shares of the medical research company's stock after selling 1,931 shares during the quarter. TD Private Client Wealth LLC's holdings in Thermo Fisher Scientific were worth $3,235,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. State Street Corp grew its position in shares of Thermo Fisher Scientific by 0.8% in the third quarter. State Street Corp now owns 16,318,961 shares of the medical research company's stock valued at $10,100,655,000 after purchasing an additional 124,996 shares during the last quarter. FMR LLC grew its holdings in Thermo Fisher Scientific by 19.7% in the 3rd quarter. FMR LLC now owns 7,877,459 shares of the medical research company's stock valued at $4,872,761,000 after buying an additional 1,294,453 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after buying an additional 127,564 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Thermo Fisher Scientific by 5.7% in the third quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock valued at $2,935,377,000 after acquiring an additional 262,062 shares during the period. Finally, Amundi grew its stake in shares of Thermo Fisher Scientific by 13.5% in the fourth quarter. Amundi now owns 2,860,847 shares of the medical research company's stock valued at $1,556,689,000 after acquiring an additional 340,263 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO traded down $0.94 on Wednesday, reaching $513.40. The stock had a trading volume of 1,216,076 shares, compared to its average volume of 1,536,507. The firm has a 50-day moving average of $544.56 and a 200-day moving average of $554.22. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a market capitalization of $193.68 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.34%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.41%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TMO. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. UBS Group boosted their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 31st. Bank of America reduced their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Finally, Raymond James reaffirmed an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.